HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Appel, S. Articles by Brossart, P. Search for Related Content PubMed PubMed Citation Articles by Appel, S. Articles by Brossart, P.

CONCISE REVIEWS

Effects of Imatinib on Normal Hematopoiesis and Immune Activation

^a Department of Hematology, Oncology and Immunology, University Medical Center, Tübingen, Germany;
^b Department of Oncology and Hematology, University Hospital Hamburg-Eppendorf, Hamburg, Germany

Key Words. Bcr-Abl • Imatinib • T cells • Dendritic cells • Hematopoiesis

Correspondence: Peter Brossart, M.D., Department of Hematology, Oncology and Immunology, University of Tübingen, Otfried-Müller Str. 10, D-72076 Tübingen, Germany. Telephone: 49-7071-2982726; Fax: 49-7071-295709; e-mail: peter.brossart{at}med.uni-tuebingen.de

The selective tyrosine kinase inhibitor imatinib (Glivec; Novartis International, Basel, Switzerland, http://www.glivec.com/content/home.jsp) is increasingly used for the treatment of Philadelphia chromosome–positive leukemias and other malignancies. In principle, the drug is well tolerated and clinical side effects are mostly moderate. However, it was shown that imatinib can affect the function of normal, nonmalignant cells, resulting in myelosuppression in treated patients. Recently, it has been demonstrated that imatinib might affect mobilization, proliferation, and differentiation of hematopoietic progenitor cells while leaving hematopoietic stem cells unaffected. Furthermore, in several in vitro studies and animal models, it was demonstrated that imatinib can affect the function and differentiation of antigen-presenting cells and inhibit the effector functions of T lymphocytes. Moreover, the induction of specific cytotoxic T cells seems to be impaired in chronic myeloid leukemia (CML) patients treated with imatinib compared with patients receiving interferon-. This is of importance because some of the therapeutic effects in the treatment of patients with CML are mediated by the induction of leukemia-specific T-cell responses. Further studies investigating the effects of imatinib on normal hematopoiesis are of interest as they might lead to a better understanding of the clinically observed side effects and also might help identify new therapeutic applications of the drug, possibly in Bcr-Abl–negative myeloproliferative disorders and potentially as an immunomodulatory agent.

This article has been cited by other articles:

				S. Jonsson, B. Olsson, C. Ohlsson, M. Lorentzon, D. Mellstrom, and H. Wadenvik Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia Haematologica, July 1, 2008; 93(7): 1101 - 1103. [Full Text] [PDF]

				F. Perros, P. Dorfmuller, R. Souza, I. Durand-Gasselin, S. Mussot, M. Mazmanian, P. Herve, D. Emilie, G. Simonneau, and M. Humbert Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension Eur. Respir. J., March 1, 2007; 29(3): 462 - 468. [Abstract] [Full Text] [PDF]

				V. G. Oehler, T. Gooley, D. S. Snyder, L. Johnston, A. Lin, C. C. Cummings, S. Chu, R. Bhatia, S. J. Forman, R. S. Negrin, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia Blood, February 15, 2007; 109(4): 1782 - 1789. [Abstract] [Full Text] [PDF]